Samsung Biologics announced on November 30 that it completed the construction of its third plant in Songdo, Incheon City after two years of construction.
The biopharmaceuticals manufacturing plant has four floors above the ground with a total floor area of 118,618 square meters. It is the largest biopharmaceuticals manufacturing plant in the world with an annual production capacity of 180,000 liters.
The annual production capacity of Samsung Biologics increased to 360,000 liters as a result of the completion of the construction. The company’s first and second plants have an annual capacity of 30,000 liters and 150,000 liters, respectively. At present, those of Lonza and Boehringer Ingelheim, which constitute the three largest contract manufacturing organizations (CMOs) in the world with Samsung Biologics, are 260,000 liters and 240,000 liters, respectively.
The completion of the construction, however, means the completion of mechanical processes in view of the characteristics of biopharmaceuticals manufacturing. Samsung Biologics is planning to start actual production after one year of testing. Commercial production is expected to be started in the latter half of 2020 after approvals are obtained from the U.S. Food and Drug Administration, the European Medicines Agency, etc.